VB
Vivacta Biotechnology
China · Biotech · Healthtech
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A+ | $50M | Apricot Capital — Role not disclosedBeijing Shunxi — Role not disclosedC&D Emerging Industry Equity Investment — Role not disclosedDecheng Capital — Role not disclosedEisai Innovation Inc. — Role not disclosedHanKang Capital — Role not disclosedLoyal Valley Capital — Role not disclosedOrbiMed — Role not disclosedQiming Venture Partners — Role not disclosed |